Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT6 receptor antagonist

Drug Development and Industrial Pharmacy

Volumn 32, Issue 2, 2006, Pages 185-196

  Hugerth, Andreas ^a,b   Brisander, Magnus ^a   Wrange, Ulla ^a   Kritikos, Mikael ^a   Norrlind, Björn ^a   Svensson, Marianne ^a   Bisrat, Mikael ^a   Östelius, Jan ^a  

^a BIOVITRUM AB   (Sweden)

^b PFIZER INC   (United States)

Author keywords

5 HT 6 receptor antagonist; Anhydrate; Hydrate; Solid state characterization; Thermal analysis

Indexed keywords

1 BENZENESULFONYL 4 (PIPERAZIN 1 YL|)INDOLE; BVT 5182; SEROTONIN 6 ANTAGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; WATER;

AQUEOUS SOLUTION; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEHYDRATION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MICROSCOPY; MORPHOLOGY; PHYSICAL CHEMISTRY; REHYDRATION; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SOLUBILITY; SUSPENSION; TEMPERATURE; THERMOGRAVIMETRY; VAPOR; X RAY DIFFRACTION;

ANTI-OBESITY AGENTS; CHEMISTRY, ANALYTICAL; DRUG STABILITY; INDOLES; PIPERAZINES; RECEPTORS, SEROTONIN, 5-HT1; SOLUBILITY; WATER;

EID: 33644998536     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500466122     Document Type: Article

References (25)

1. Berbenni, V., Marini, A., Bruni, G., & Cardini, A. (2001). Thermo-analytical and spectroscopic characterization of solid-state retinoic acid. Int. J. Pharm., 221, 123-141.
2. Byrn, S. R., Pfeiffer, R. R., & Stowell, J. G. (1999). Solid-state Chemistry of Drugs, (2nd Ed.). West Lafayette: SSCI, Inc., 574.
3. Caira, M. R., Bettinetti, G., & Sorrenti, M. (2002). Structural relationships, thermal properties, and physicochemical characterization of anhydrous and solvated crystalline forms of textroprim. J. Pharm. Sci., 91, 467-481.
4. Gäfvert, E. (2003). Internal communication (Measurements performed with Sirius Analytical Instruments Ltd., East Sussex, UK).
5. Kohlbeck, F., & Hörl, E. M. (1976). Indexing program for powder patterns especialy suitable for triclinic, monoclinic, and orthorhombic lattices. J. Appl. Cryst., 9, 28-33.
6. Kohlbeck, F., & Hörl, E. M. (1978). Trial and error indexing program for powder patterns of monodinic substances. J. Appl. Cryst., 11, 60-61.
7. Marti, E. E., Kaisersberger, E. W., Kaiser, G. H., & Ma, W.-Y. (2000). Netzsch annual 2000. Thermoanalytical characterization of pharmaceuticals, Netzsch-Gerätebau GmbH, Selb, 94-99.
8. Morris, K. R., & Rodriguez-Hornedo, N. (1992). Hydrates. In Encyclopedia of Pharmaceutical Technology, Swarbrick, J., & Boylan, J. C., Eds.; New York: Marcel Dekker Inc., vol. 7, 393-440.
9. Nakanishi, K. (1962). Infrared absorption spectroscopy. Practical, Nankodo Co Ltd, Tokyo, 30 and 210.
10. Perrier, P. R., & Byrn, S. R. (1982). Influence of crystal packing on the solid-state desolvation of purine and pyrimidine hydrates: Loss of water of crystallization from thymine monohydrate, cystine monohydrate, 5-nitrouracil monohydrate and 2′-deoxyadenosine monohydrate. J. Org. Chem., 47, 4671-4676.
11. Reutzel-Edens, S. M., Kleeman, R. L., Lewellen, P. L., Borghese, A. L., & Antoine, L. J. (2003). Crystal form of LY334370 HCl: Isolation, solid-state characterization and physicochemical properties. J. Pharm. Sci., 92, 1196-1205.
12. Sacchetti, M. (2004). Determining the relative physical stability of anhydrous and hydrous crystal forms of GW2016. Int. J. Pharm., 273, 195-202.
13. Shirley, R. (2004). The CRYSFIRE System for Automatic Powder Indexing: User's Manual. 41 Guildford Park Avenue. Surrey, GU2/NL, England: The Lattice Press.
14. Socrates, G. (1994). Infrared characteristic group frequencies. Chichester: Wiley, 11.
15. U.S Pharmacopeia, X., US Pharmacopeial Convention, Rockville, 2002, 2011-2012.
16. Vippagunta, S. R., Brittain, H. G., & Grant, D. J. W. (2001). Crystalline solids. Ad. Drug Deliv. Rev., 48, 3-26.
17. Werner, P.-E. (1969). A fortran program for least-squares refinement of crystal structure dimensions. Arkiv Kemi, 31, 513-516.
18. Werner, P.-E., Eriksson, L., & Westdahl, M. (1985). Treor, a semi-exhaustive trial-and-error powder indexing program for al symmetries. J. Appl. Crystallography., 18, 108-113.
19. 6 receptors. Curr. Drug Target CNS Neurol. Disord., 3, 59-79.
20. Zhu, H., Yuen, C., & Grant, D. J. (1996). Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Theophylline. Int. J. Pharm., 135, 151-160.
21. Zhu, H., & Grant, D. J. (1996). Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 2. Ampicillin. Int. J. Pharm., 139, 33-43.
22. Zhu, H., Khankari, R. K., Padden, B. E., Munson, E. J., Gleason, W. B., & Grant, D. J. W. (1996). Physicochemical characterization of nedocromil bivalent metal salt hydrates. 1. Nedocromil magnesium. J. Pharm. Sci., 85, 1026-1034.
23. Zhu, H., Padden, B. E., Munson, E. J., & Grant, D. J. W. (1997a). Physico-chemical characterization of nedocromil bivalent metal salt hydrates. 2. Nedocromil zinc J. Pharm. Sci., 86, 418-429.
24. Zhu, H., Halfen, J. A., Young, V. G., Padden, B. E., Munson, E. J., Menon, V., & Grant, D. J. W. (1997b). Physicochemical characterization of nedocromil bivalent metal salt hydrates 3. Nedocromil calcium J. Pharm. Sci., 86, 1439-1447.
25. Zografi, G. (1998). States of water associated with solids. Drug Dev. Ind. Pharm., 14, 1905-1926.